GlaxoSmithKline

Auxilium and GSK to co-promote Testim in U.S.

Monday, May 21, 2012 12:35 PM

Auxilium Pharmaceuticals, a specialty biopharmaceutical company based in Malvern, Penn., and GlaxoSmithKline LLC, the U.S. subsidiary of GlaxoSmithKline plc, have entered into an agreement for the co-promotion of Auxilium’s Testim 1% (testosterone gel), which is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of testosterone.

More... »


GlaxoSmithKline to fully acquire Cellzome for $97.2 million

Wednesday, May 16, 2012 10:47 AM

GlaxoSmithKline has entered into an agreement with Cellzome, a privately-held chemical proteomics company, to acquire all shares in the company it does not currently own for $99 million in cash. Cellzome, which has laboratories in Cambridge, U.K., and Heidelberg, Germany, will become part of GSK's R&D organization.

More... »


GSK offers $13 per share for HGS

Wednesday, May 9, 2012 11:46 PM

GlaxoSmithKline will not participate in Human Genome Sciences’ strategic alternatives review process and will instead commence a tender offer this week to acquire all outstanding shares of HGS for $13.00 per share in cash.

More... »

GSK adds two non-executive directors to its board

Friday, May 4, 2012 08:00 AM

GlaxoSmithKline (GSK) has appointed Lynn Elsenhans and Jing Ulrich as non-executive directors to the company’s board, beginning July 1, 2012.

More... »

Report: Pharmaceutical market grew by 5.3% in 2011

Friday, April 20, 2012 12:29 PM

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, found that in 2011, the global pharmaceutical market, in dollar terms, benefitted significantly from positive currency effects.

More... »

HGS refuses GSK unsolicited offer, considers alternatives

Friday, April 20, 2012 11:21 AM

Human Genome Sciences has refused GlaxoSmithKline’s unsolicited offer on April 11 proposing to acquire all of the outstanding shares of HGS for $13.00 per share in cash ($2.6 billion), an 81% premium to closing share price on April 18.

More... »

Five Prime and GSK form second strategic alliance

Wednesday, April 18, 2012 02:28 PM

Five Prime Therapeutics, a biotech based in San Francisco, has entered into its second strategic drug discovery alliance with GlaxoSmithKline in two years.

More... »

Mymetics ropes in Dendreon vets

Wednesday, April 11, 2012 12:58 PM

Mymetics, a Swiss-based biotech of mucosal and virosomal-based vaccines for infectious diseases, has appointed Grant E. Pickering as president and CEO and Christopher S. Henney as chairman of the board of directors. The changes were made in connection with Mymetics’ efforts to obtain additional financing and to advance the development of its vaccine platform.

More... »

Syndax initiates phase I/II study in metastatic breast cancer

Monday, April 9, 2012 04:42 PM

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company based in Waltham, Mass., has initiated a phase I/II study combining its lead product entinostat with lapatinib ditosylate (Tykerb) in patients with locally recurrent or distant relapsed metastatic breast cancer previously treated with trastuzumab (Herceptin).

More... »

GSK invests $794 million in U.K., creates jobs

Friday, March 23, 2012 12:44 PM

GlaxoSmithKline will invest more than $794 million in the U.K. across its manufacturing sites and a new facility in Cumbria to increase production of key active ingredients for its pharmaceutical products and vaccines, creating 1,000 new jobs.

More... »


CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs